Anke Biotech announced that Shanghai Soho Yiming Pharmaceutical Co., Ltd., the company's wholly-owned subsidiary, recently received the “Notice of Approval of Application for the Marketing Application of Chemical Ingredients” for the active ingredient terlipressin acetate issued by the State Drug Administration. The API has been approved for listing and can be used in the production of terlipressin preparations, which is conducive to enriching the company's peptide API product pipeline.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.